In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging

Molecular Imaging

Volumn 11, Issue 3, 2012, Pages 177-186

  Hassan, Moinuddin ^a   Chernomordik, Victor ^a   Zielinski, Rafal ^a   Ardeshirpour, Yasaman ^a   Capala, Jacek ^a   Gandjbakhche, Amir ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17-DMAG; AFFIBODY MOLECULES; AFTER-TREATMENT; ANTIANGIOGENIC; BINDING KINETICS; BREAST CARCINOMAS; DOWN-REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX-VIVO; EXPRESSION LEVELS; FLUORESCENCE IMAGE; FLUORESCENCE IMAGING; HUMAN EPIDERMAL GROWTH FACTOR; IN-VIVO; NEAR-INFRARED FLUORESCENCE IMAGING; NEAR-INFRARED OPTICAL IMAGING; OVER-EXPRESSION; THERAPEUTIC STRATEGY; TIME SEQUENCES;

ANIMALS; BIOMARKERS; INFRARED DEVICES; PROBES; TUMORS;

FLUORESCENCE;

17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ALVESPIMYCIN; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; METHODOLOGY; MOUSE; NUDE MOUSE; PROTO ONCOGENE; SPECTROFLUOROMETRY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SPECTROMETRY, FLUORESCENCE;

EID: 84862702785     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00038     Document Type: Article

References (27)

1. Allison M. Biomarker-led adaptive trial blazes a trail in breast cancer. Nat Biotechnol 2010;28:383-4, doi:10.1038/nbt0510-383.
2. Hillman EM, Moore A. All-optical anatomical co-registration for molecular imaging of small animals using dynamic contrast. Nat Photonics 2007;1:526-30, doi:10.1038/nphoton. 2007.146.
3. Allred DC. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone. J Natl Cancer Inst 2010;102:585-7, doi:10.1093/jnci/djq118.
4. Phillips KA, Marshall DA, Haas JS, et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009;115:5166-74, doi:10.1002/cncr.24574.
5. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006;12:6326-30, doi:10.1158/1078-0432. CCR-06-1732. (Pubitemid 44799700)
6. Dierkes T, Grosenick D, Moesta KT, et al. Reconstruction of optical properties of phantom and breast lesion in vivo from paraxial scanning data. Phys Med Biol 2005;50:2519-42, doi:10. 1088/0031-9155/50/11/006. (Pubitemid 40770637)
7. Grosenick D, Moesta KT, Moller M, et al. Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients. Phys Med Biol 2005;50:2429-49, doi:10. 1088/0031-9155/50/11/001. (Pubitemid 40770632)
8. Grosenick D, Moesta KT, Wabnitz H, et al. Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors. Appl Opt 2003;42:3170-86, doi:10.1364/AO.42.003170.
9. Grosenick D, Wabnitz H, Moesta KT, et al. Concentration and oxygen saturation of haemoglobin of 50 breast tumours determined by time-domain optical mammography. Phys Med Biol 2004;49:1165-81, doi:10.1088/0031-9155/49/7/006. (Pubitemid 38514782)
10. Grosenick D, Wabnitz H, Moesta KT, et al. Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas. Phys Med Biol 2005;50:2451-68, doi:10.1088/0031-9155/50/11/002. (Pubitemid 40770633)
11. Intes X. Time-domain optical mammography SoftScan: initial results. Acad Radiol 2005;12:934-7, doi:10.1016/j.acra.2005.05.006. (Pubitemid 41116410)
12. Ntziachristos V, Yodh AG, Schnall M, et al. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 2000;97:2767-72, doi:10.1073/pnas.040570597. (Pubitemid 30159246)
13. Rinneberg H, Grosenick D, Moesta KT, et al. Scanning timedomain optical mammography: detection and characterization of breast tumors in vivo. Technol Cancer Res Treat 2005;4:483-96. (Pubitemid 41446802)
14. Pleijhuis RG, Langhout GC, Helfrich W, et al. Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur J Surg Oncol 2011;37:32-9.
15. Kramer-Marek G, Kiesewetter DO Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18) F-labeled Affibody molecules. J Nucl Med 2009;50:1131-9, doi:10.2967/jnumed.108. 057695.
16. Kramer-Marek G, Kiesewetter DO, Martiniova L, et al. [18F]FBEM-Z (HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008-18, doi:10.1007/s00259-007-0658-0.
17. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-80, doi:10.1016/j.febslet.2010.04.014.
18. Lundberg E, Hoiden-Guthenberg I, Larsson B, et al. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 2007;319:53-63, doi:10.1016/j.jim.2006.10.013. (Pubitemid 46107467)
19. Zielinski R, Lyakhov I, Jacobs A, et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 2009;32:817-25, doi:10.1097/CJI.0b013e3181ad4d5d.
20. Hassan M, Riley J, Chernomordik V, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007;6:229-36. (Pubitemid 47509827)
21. Chernomordik V, Hassan M, Lee SB, et al. Quantitative analysis of HER2 receptors expression in vivo by near-infrared optical imaging. Mol Imaging 2010;9:192-200.
22. Crawley MJ. Statistics: an introduction using R, exercises, 4. Regression. Available at: http://www3.imperial.ac.uk/pls/portallive/docs/1/ 1171920.PDF.
23. Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10:4813-21, doi:10.1158/1078-0432. CCR-03-0795. (Pubitemid 38955535)
24. Bouchelouche K Capala J. 'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol 2010;22:274-80, doi:10.1097/CCO. 0b013e3283373d5c.
25. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008;14:2999-3019, doi:10.2174/138161208786404290.
26. De Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci U S A 2003;100:12337-42, doi:10.1073/pnas.2031337100. (Pubitemid 37271561)
27. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-32, doi:10.1158/1535-7163. MCT-05-0439.